Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Inhibition of IL-23 mediated inflammation with a novel small molecule inverse agonist of RORgt.

Gauld S, Jacquet S, Gauvin D, Wallace C, Wang Y, McCarthy R, Goess C, Leys L, Huang S, Su Z, Edelmayer R, Wetter J, Salte K, McGaraughty S, Argiriadi M, Honore P, Luccarini JM, Bressac D, Desino K, Breinlinger E, Cusack K, Potin D, Kort M, Masson P.

J Pharmacol Exp Ther. 2019 Aug 2. pii: jpet.119.258046. doi: 10.1124/jpet.119.258046. [Epub ahead of print]

2.

Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORγ inverse agonists.

Amaudrut J, Argiriadi MA, Barth M, Breinlinger EC, Bressac D, Broqua P, Calderwood DJ, Chatar M, Cusack KP, Gauld SB, Jacquet S, Kamath RV, Kort ME, Lepais V, Luccarini JM, Masson P, Montalbetti C, Mounier L, Potin D, Poupardin O, Rouaud S, Spitzer L, Wallace CD.

Bioorg Med Chem Lett. 2019 Jul 15;29(14):1799-1806. doi: 10.1016/j.bmcl.2019.05.015. Epub 2019 May 9.

PMID:
31101472
3.

Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.

Boubia B, Poupardin O, Barth M, Binet J, Peralba P, Mounier L, Jacquier E, Gauthier E, Lepais V, Chatar M, Ferry S, Thourigny A, Guillier F, Llacer J, Amaudrut J, Dodey P, Lacombe O, Masson P, Montalbetti C, Wettstein G, Luccarini JM, Legendre C, Junien JL, Broqua P.

J Med Chem. 2018 Mar 22;61(6):2246-2265. doi: 10.1021/acs.jmedchem.7b01285. Epub 2018 Feb 27.

PMID:
29446942
4.

The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis.

Wettstein G, Luccarini JM, Poekes L, Faye P, Kupkowski F, Adarbes V, Defrêne E, Estivalet C, Gawronski X, Jantzen I, Philippot A, Tessier J, Tuyaa-Boustugue P, Oakley F, Mann DA, Leclercq I, Francque S, Konstantinova I, Broqua P, Junien JL.

Hepatol Commun. 2017 Jun 19;1(6):524-537. doi: 10.1002/hep4.1057. eCollection 2017 Aug.

5.

Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension.

Avouac J, Konstantinova I, Guignabert C, Pezet S, Sadoine J, Guilbert T, Cauvet A, Tu L, Luccarini JM, Junien JL, Broqua P, Allanore Y.

Ann Rheum Dis. 2017 Nov;76(11):1931-1940. doi: 10.1136/annrheumdis-2016-210821. Epub 2017 Aug 11.

PMID:
28801346
6.

Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.

Ruzehaji N, Frantz C, Ponsoye M, Avouac J, Pezet S, Guilbert T, Luccarini JM, Broqua P, Junien JL, Allanore Y.

Ann Rheum Dis. 2016 Dec;75(12):2175-2183. doi: 10.1136/annrheumdis-2015-208029. Epub 2016 Mar 9.

7.

From bradykinin B2 receptor antagonists to orally active and selective bradykinin B1 receptor antagonists.

Barth M, Bondoux M, Luccarini JM, Peyrou V, Dodey P, Pruneau D, Massardier C, Paquet JL.

J Med Chem. 2012 Mar 22;55(6):2574-84. doi: 10.1021/jm2016057. Epub 2012 Mar 6.

PMID:
22369198
8.

Antinociceptive pharmacology of N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl) sulfonyl]methylamino]ethoxy]-N-methylacetamide, fumarate (LF22-0542), a novel nonpeptidic bradykinin B1 receptor antagonist.

Porreca F, Vanderah TW, Guo W, Barth M, Dodey P, Peyrou V, Luccarini JM, Junien JL, Pruneau D.

J Pharmacol Exp Ther. 2006 Jul;318(1):195-205. Epub 2006 Mar 24.

PMID:
16565167
9.

Cloning and characterization of guinea pig interleukin-8 receptor.

Catusse J, Faye P, Loillier B, Cremers B, Franck RM, Luccarini JM, Pruneau D, Paquet JL.

Biochem Pharmacol. 2003 Oct 1;66(7):1171-80.

PMID:
14505796
10.

A rational approach to the design and synthesis of a new bradykinin B(1) receptor antagonist.

Bedos P, Amblard M, Subra G, Dodey P, Luccarini JM, Paquet JL, Pruneau D, Aumelas A, Martinez J.

J Med Chem. 2000 Jun 15;43(12):2387-94.

PMID:
10882365
11.

Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists.

Amblard M, Bedos P, Olivier C, Daffix I, Luccarini JM, Dodey P, Pruneau D, Paquet JL, Martinez J.

J Med Chem. 2000 Jun 15;43(12):2382-6.

PMID:
10882364
12.

Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist.

Pruneau D, Paquet JL, Luccarini JM, Defrêne E, Fouchet C, Franck RM, Loillier B, Robert C, Bélichard P, Duclos H, Cremers B, Dodey P.

Immunopharmacology. 1999 Sep;43(2-3):187-94.

PMID:
10596852
13.

Specific nonpeptide photoprobes as tools for the structural study of the angiotensin II AT(1) receptor.

Nouet S, Dodey PR, Bondoux MR, Pruneau D, Luccarini JM, Groblewski T, Larguier R, Lombard C, Marie J, Renaut PP, Leclerc G, Bonnafous JC.

J Med Chem. 1999 Nov 4;42(22):4572-83.

PMID:
10579820
14.

Synthesis and characterization of bradykinin B(2) receptor agonists containing constrained dipeptide mimics.

Amblard M, Daffix I, Bergé G, Calmès M, Dodey P, Pruneau D, Paquet JL, Luccarini JM, Bélichard P, Martinez J.

J Med Chem. 1999 Oct 7;42(20):4193-201.

PMID:
10514289
15.

Design and synthesis of potent bradykinin agonists containing a benzothiazepine moiety.

Amblard M, Daffix I, Bedos P, Bergé G, Pruneau D, Paquet JL, Luccarini JM, Bélichard P, Dodey P, Martinez J.

J Med Chem. 1999 Oct 7;42(20):4185-92.

PMID:
10514288
16.

Pharmacological and molecular evidence for kinin B1 receptor expression in urinary bladder of cyclophosphamide-treated rats.

Belichard P, Luccarini JM, Defrêne E, Faye P, Franck RM, Duclos H, Paquet JL, Pruneau D.

Br J Pharmacol. 1999 Sep;128(1):213-9.

17.

Pharmacological characterization of the bradykinin B2 receptor: inter-species variability and dissociation between binding and functional responses.

Paquet JL, Luccarini JM, Fouchet C, Defrêne E, Loillier B, Robert C, Bélichard P, Cremers B, Pruneau D.

Br J Pharmacol. 1999 Mar;126(5):1083-90.

18.

In vitro and in vivo effects of the new nonpeptide bradykinin B2 receptor antagonist, LF 16-0335C, on guinea-pig and rat kinin receptors.

Pruneau D, Luccarini JM, Fouchet C, Defrêne E, Franck RM, Loillier B, Duclos H, Robert C, Cremers B, Bélichard P, Paquet JL.

Fundam Clin Pharmacol. 1999;13(1):75-83.

PMID:
10027091
19.

LF 16.0335, a novel potent and selective nonpeptide antagonist of the human bradykinin B2 receptor.

Pruneau D, Luccarini JM, Fouchet C, Defrêne E, Franck RM, Loillier B, Duclos H, Robert C, Cremers B, Bélichard P, Paquet JL.

Br J Pharmacol. 1998 Sep;125(2):365-72.

20.

Synthesis and pharmacological evaluation of dimer derivatives of the bradykinin receptor antagonist HOE-140.

Daffix I, Amblard M, Bergé G, Dodey P, Pruneau D, Paquet JL, Fouchet C, Franck RM, Defrêne E, Luccarini JM, Bélichard P, Martinez J.

J Pept Res. 1998 Jul;52(1):1-14.

PMID:
9716245
21.

Haemodynamic and cardiac effects of kinin B1 and B2 receptor stimulation in conscious instrumented dogs.

Bélichard P, Loillier B, Paquet JL, Luccarini JM, Pruneau D.

Br J Pharmacol. 1996 Apr;117(7):1565-71.

22.

Characterisation of bradykinin receptors from juvenile pig coronary artery.

Pruneau D, Luccarini JM, Defrêne E, Paquet JL, Bélichard P.

Eur J Pharmacol. 1996 Feb 15;297(1-2):53-60.

PMID:
8851166
23.

Pharmacological evidence for a single bradykinin B2 receptor in the guinea-pig.

Pruneau D, Luccarini JM, Defrêne E, Paquet JL, Bélichard P.

Br J Pharmacol. 1995 Oct;116(3):2106-12.

24.
25.

Induction of kinin B1 receptor-dependent vasoconstriction following balloon catheter injury to the rabbit carotid artery.

Pruneau D, Luccarini JM, Robert C, Bélichard P.

Br J Pharmacol. 1994 Apr;111(4):1029-34.

26.

[Evaluation of an apparatus to study the erythrocyte filterability by filtration pressure for a routine clinical use: the erythrometer].

Stoltz JF, Haan P, Duvivier C, Luccarini JM, Chicaud P.

Agressologie. 1984 Jan;25(1):35-7. French. No abstract available.

PMID:
6721062

Supplemental Content

Loading ...
Support Center